| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Michael Simons | Q39375925 |
| P2093 | author name string | Daniela Tirziu | |
| P2860 | cites work | Nitric oxide synthase in cardiac sarcoplasmic reticulum | Q22008689 |
| Cardiomyocytes as effectors of nitric oxide signalling | Q24310604 | ||
| Nitric oxide: physiology, pathophysiology, and pharmacology | Q26778243 | ||
| Caveolae and caveolins in the cardiovascular system | Q28266609 | ||
| Cardiomyocyte GATA4 functions as a stress-responsive regulator of angiogenesis in the murine heart | Q28509556 | ||
| RGS4 inhibits G-protein signaling in cardiomyocytes | Q28568425 | ||
| Enhancement of ischemia-induced angiogenesis by eNOS overexpression | Q30877936 | ||
| The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals | Q33688733 | ||
| Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load | Q33743649 | ||
| RGS4 causes increased mortality and reduced cardiac hypertrophy in response to pressure overload | Q33857945 | ||
| Paracrine and autocrine effects of nitric oxide on myocardial function | Q33889121 | ||
| Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve | Q33911425 | ||
| Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes | Q34038333 | ||
| RGS4 and RGS5 are in vivo substrates of the N-end rule pathway | Q34085136 | ||
| Expression of ten RGS proteins in human myocardium: functional characterization of an upregulation of RGS4 in heart failure. | Q34144328 | ||
| The role of nitric oxide in the failing heart | Q34222988 | ||
| Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice | Q34961540 | ||
| Regulators of G-protein signalling: multifunctional proteins with impact on signalling in the cardiovascular system. | Q35057155 | ||
| Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload | Q35095396 | ||
| Biochemistry of Nitric Oxide and Its Redox-Activated Forms | Q35159350 | ||
| Nitric oxide and cardiac function: ten years after, and continuing | Q35213031 | ||
| Molecular mechanisms in endothelial regulation of cardiac function. | Q35584846 | ||
| The endocardial endothelial Na+/K+ ATPase and cardiac contraction. | Q35751469 | ||
| Interference of antihypertrophic molecules and signaling pathways with the Ca2+-calcineurin-NFAT cascade in cardiac myocytes | Q35846926 | ||
| Myocardial hypertrophy in the absence of external stimuli is induced by angiogenesis in mice | Q36099401 | ||
| Follistatin induction by nitric oxide through cyclic GMP: a tightly regulated signaling pathway that controls myoblast fusion | Q36116815 | ||
| Regulation of the mammalian heart function by nitric oxide. | Q36177896 | ||
| Cell signalling diversity of the Gqalpha family of heterotrimeric G proteins | Q36267106 | ||
| Caveolins and the regulation of endothelial nitric oxide synthase in the heart | Q36399015 | ||
| Follistatin-like 1, a secreted muscle protein, promotes endothelial cell function and revascularization in ischemic tissue through a nitric-oxide synthase-dependent mechanism | Q36973708 | ||
| Follistatin-like 1 is an Akt-regulated cardioprotective factor that is secreted by the heart | Q37184799 | ||
| Endothelium as master regulator of organ development and growth. | Q37274182 | ||
| The sarcolemmal calcium pump, alpha-1 syntrophin, and neuronal nitric-oxide synthase are parts of a macromolecular protein complex | Q40273656 | ||
| Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease | Q40678937 | ||
| The cardiac endothelium: cardioactive mediators | Q41274671 | ||
| Cardiac growth and angiogenesis coordinated by intertissue interactions | Q42239503 | ||
| Activation of distinct cAMP-dependent and cGMP-dependent pathways by nitric oxide in cardiac myocytes | Q42472045 | ||
| Are myocardial eNOS and nNOS involved in the beta-adrenergic and muscarinic regulation of inotropy? A systematic investigation | Q42492279 | ||
| Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure | Q42928039 | ||
| Distribution and role of Na(+)/K(+) ATPase in endocardial endothelium | Q43818613 | ||
| Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms | Q43926534 | ||
| Role of cyclic GMP-dependent protein kinase in the contractile response to exogenous nitric oxide in rat cardiac myocytes | Q43961407 | ||
| Akt signaling mediates postnatal heart growth in response to insulin and nutritional status | Q44090717 | ||
| Overexpression of endothelial nitric oxide synthase attenuates cardiac hypertrophy induced by chronic isoproterenol infusion | Q44133086 | ||
| Downregulation of cytoskeletal muscle LIM protein by nitric oxide: impact on cardiac myocyte hypertrophy | Q44365419 | ||
| Human endothelial nitric oxide synthase gene delivery protects against cardiac remodeling and reduces oxidative stress after myocardial infarction | Q46373231 | ||
| The N-end rule pathway as a nitric oxide sensor controlling the levels of multiple regulators | Q46742633 | ||
| LA419, a novel nitric oxide donor, prevents pathological cardiac remodeling in pressure-overloaded rats via endothelial nitric oxide synthase pathway regulation. | Q46913436 | ||
| Pressure overload-induced LV hypertrophy and dysfunction in mice are exacerbated by congenital NOS3 deficiency | Q48932851 | ||
| Paracrine coronary endothelial control of left ventricular function in humans. | Q50594479 | ||
| Mechanisms of reduced nitric oxide/cGMP-mediated vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. | Q54043767 | ||
| Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. | Q54151586 | ||
| Vasomotor control in mice overexpressing human endothelial nitric oxide synthase | Q61976448 | ||
| Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. | Q64980431 | ||
| VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts | Q71139703 | ||
| 8-bromo-cGMP reduces the myofilament response to Ca2+ in intact cardiac myocytes | Q72360226 | ||
| Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect | Q73358586 | ||
| RGS4 reduces contractile dysfunction and hypertrophic gene induction in Galpha q overexpressing mice | Q73404390 | ||
| Phenotyping hypertrophy: eschew obfuscation | Q73521063 | ||
| Modulation of mouse cardiac function in vivo by eNOS and ANP | Q73532335 | ||
| Hemodynamic effects of intracoronary VEGF delivery: evidence of tachyphylaxis and NO dependence of response | Q73757619 | ||
| Nonuniformity of endothelial constitutive nitric oxide synthase distribution in cardiac endothelium | Q74191233 | ||
| Molecular multitasking: statins lead to more arteries, less plaque | Q74268505 | ||
| VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells | Q74408747 | ||
| Endothelial nitric oxide synthase activity is essential for vasodilation during blood flow recovery but not for arteriogenesis | Q80447555 | ||
| Nitric oxide inhibits endothelin-1-induced cardiomyocyte hypertrophy through cGMP-mediated suppression of extracellular-signal regulated kinase phosphorylation | Q80947375 | ||
| P433 | issue | 8 | |
| P921 | main subject | endothelium | Q111140 |
| P1104 | number of pages | 7 | |
| P304 | page(s) | 299-305 | |
| P577 | publication date | 2008-11-01 | |
| P1433 | published in | Trends in Cardiovascular Medicine | Q1850265 |
| P1476 | title | Endothelium-driven myocardial growth or nitric oxide at the crossroads | |
| P478 | volume | 18 |
| Q34782165 | Activation of group VI phospholipase A2 isoforms in cardiac endothelial cells |
| Q40956179 | Augmented endothelial l-arginine transport ameliorates pressure-overload-induced cardiac hypertrophy |
| Q64951075 | Biomarkers of Oxidative Stress in Metabolic Syndrome and Associated Diseases. |
| Q35204828 | Cardiac NO signalling in the metabolic syndrome |
| Q30546913 | Cardiomyocyte FGF signaling is required for Cx43 phosphorylation and cardiac gap junction maintenance |
| Q39576954 | Cardioprotective Effect of Ulmus wallichiana Planchon in β-Adrenergic Agonist Induced Cardiac Hypertrophy |
| Q37784108 | Cell communications in the heart. |
| Q35601964 | Elimination of vitamin D receptor in vascular endothelial cells alters vascular function |
| Q33750766 | Growth inhibition of human breast carcinoma cells by overexpression of regulator of G-protein signaling 4. |
| Q37998444 | Importance of myocyte-nonmyocyte interactions in cardiac development and disease |
| Q58616874 | Mechanical Stretching Simulates Cardiac Physiology and Pathology through Mechanosensor Piezo1 |
| Q36733421 | NO triggers RGS4 degradation to coordinate angiogenesis and cardiomyocyte growth |
| Q37786171 | The role of nuclear factor kappa B and nitric oxide interaction in heart remodelling |
Search more.